Results 231 to 240 of about 13,963,189 (308)

Safety and efficacy of PD-1/PD-L1 inhibitors combined with albumin-bound paclitaxel and fluorouracil-based agents as second-line therapy in biliary tract cancers. [PDF]

World J Surg Oncol
Wang X, Zha Y, Li P, Fu S, Xu L, Jiang W, Wu J, Mao Y.   +7 more
europepmc   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source

First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study. [PDF]

Kidney Med
Wang L, Yang M, Yan L, Shao F.
europepmc   +1 more source

Dolutegravir for second-line antiretroviral therapy: the beat goes on

The Lancet Global Health
Nosipho, Shangase, Tendesayi, Kufa
openaire   +2 more sources

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B. [PDF]

Nat Commun
Lee KW, Mahalingam D, Shim BY, Kim IH, Oh DY, Uronis H, Sym SJ, Sonbol M, Almhanna K, Tejani MA, Kang B, Kagey MH, Stilian M, Jia C, Sirard CA, Altura R, Ajani JA, Klempner SJ.   +17 more
europepmc   +1 more source

Integrating Time‐Adjusted Imaging Instability Into Functional Outcome Prediction After Intracerebral Hemorrhage: Development and Validation of the HAGIV Score

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Early risk stratification may support clinical decision‐making in spontaneous intracerebral hemorrhage (ICH). We aimed to develop and internally validate HAGIV, a score integrating frequency of imaging markers (FIM), a time‐adjusted non‐contrast computed tomography (CT) metric of hematoma expansion, with established predictors for 90‐
Lei Song, Ren Ke, Anqi Chen, Yufei Fu, Hang Zhou, Rujia Wang, Liwei Zou, Yongqiang Yu, Ming Yuan, Xiaoming Qiu, Mengzhou Xue   +10 more
wiley   +1 more source

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study. [PDF]

Ann Hematol
Tu Y, Yang L, Cheng Y, Zhang Y, Lu Y, Xu S, Li X, Xu M, Xiang M, Fan Y, Ru Y, Xu Y, Chen F, Wu X, Zheng Y, Li F, Han Y, Tang X, Qiu H, Miao M, Zhao Y, Zhu X, Wu D, Chen J.   +23 more
europepmc   +1 more source

Digital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Use

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Primary mitochondrial disease is a group of genetic disorders caused by pathogenic variants in nuclear or mitochondrial DNA, often resulting in progressive neurodegeneration and cognitive decline. Current management is primarily supportive, though recent research offers hope for disease‐modifying treatments in the future.
Oksana Pogoryelova, Jan Smeitink, Herma Renkema, Rosabeth White, Frankie Barton, Rachel Lyon, Jane Newman, Aye Moe, Yi Shiau Ng, Grainne Siobhan Gorman   +9 more
wiley   +1 more source

Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry. [PDF]

ACR Open Rheumatol
Baker JF, Mizelle KV, Saikali W, Moore PC, Kang HJ, Gruben D, Shelbaya A, Stockert L, O'Brien J.   +8 more
europepmc   +1 more source